1-3 of 3
L. Claire Tsao
Close
Sort by
Journal Articles

Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib

Inhye E. Ahn, MD, Xin Tian, Maher Albitar, MD, Sarah E. M. Herman, PhD, Erika M. Cook, Susan Soto, Wanlong Ma, David Ipe, L. Claire Tsao, Mei Cheng, James P. Dean, Adrian Wiestner, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 186.
https://doi.org/10.1182/blood-2018-99-110326
Published: 2018
Journal Articles

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

Clinical Trials & Observations
Andrzej Jakubowiak, Massimo Offidani, Brigitte Pégourie, Javier De La Rubia, Laurent Garderet, Kamel Laribi, Alberto Bosi, Roberto Marasca, Jacob Laubach, Ann Mohrbacher, Angelo Michele Carella, Anil K. Singhal, L. Claire Tsao, Mark Lynch, Eric Bleickardt, Ying-Ming Jou, Michael Robbins, Antonio Palumbo
Journal: Blood
Blood (2016) 127 (23): 2833–2840.
https://doi.org/10.1182/blood-2016-01-694604
Published: 2016
Includes: Supplemental data
Journal Articles

Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Paul G. Richardson, Sundar Jagannath, MD, Philippe Moreau, MD, Andrzej Jakubowiak, MD PhD, Marc S Raab, MD PhD, Thierry Facon, MD, Ravi Vij, MD, Darrell White, MD, Donna E. Reece, MD, Lotfi Benboubker, MD PhD, Jeffrey Zonder, MD, L. Claire Tsao, PhD, Kenneth C. Anderson, MD, Eric Bleickardt, MD, Anil K Singhal, MD, Sagar Lonial, MD
Journal: Blood
Blood (2014) 124 (21): 302.
https://doi.org/10.1182/blood.V124.21.302.302
Published: 2014